S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

Bibliographic Details
Main Authors:	Nausheen Ahmed, Swetha Kambhampati, Mehdi Hamadani, Natalie Grover, Mazyar Shadman, Frederick Locke, James Gerson, Matthew J. Frank, L. Elizabeth Budde, Michael Wang, Zhen-Huan Hu, Ana Nunes, David Dalton, Ioana Kloos, Daniel Lee, Hairong Xu, Marcelo Pasquini, Alex F. Herrera
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967792.43327.c1

Similar Items

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
by: F. Locke, MD, et al.
Published: (2022-06-01)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
by: Enver Aydilek, et al.
Published: (2023-09-01)

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
by: Charles Herbaux, et al.
Published: (2024-06-01)

Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma
by: François Volery, et al.
Published: (2024-09-01)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
by: O'Reilly, MA, et al.
Published: (2024)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
by: Maeve A. O'Reilly, et al.
Published: (2024-06-01)

Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
by: Kopmar NE, et al.
Published: (2024-11-01)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
by: Y. Wang, et al.
Published: (2022-06-01)

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
by: Graeme Ball, et al.
Published: (2022-03-01)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
by: Monia Marchetti
Published: (2023-08-01)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
by: Daniel J DeAngelo, et al.
Published: (2023-08-01)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
by: Nuria Martinez-Cibrian, et al.
Published: (2023-08-01)

Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
by: Erin A. Dean, MD, et al.
Published: (2023-03-01)

P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
by: Bijal Shah, et al.
Published: (2023-08-01)

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
by: Frederick L Locke, et al.
Published: (2025-02-01)

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2
by: H Einsele, et al.
Published: (2021-10-01)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
by: Zhitao Ying, et al.
Published: (2021-02-01)

MATCHED-SIBLING, MATCHED-UNRELATED, OR HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LEUKEMIAS AND MYELODYSPLASIA IN BRAZIL: A PROSPECTIVE MULTICENTER STUDY IN COLLABORATION WITH THE CIBMTR
by: LJ Arcuri, et al.
Published: (2024-10-01)

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
by: Nirav N. Shah, et al.
Published: (2018-04-01)

Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China
by: Hui Li, et al.
Published: (2024-05-01)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
by: N. van de Donk, et al.
Published: (2023-05-01)

The CEL
by: Cibin, Alberto
Published: (2012-03-01)

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
by: Doris K. Hansen, et al.
Published: (2024-06-01)

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study
by: Tao Zhang, et al.
Published: (2023-04-01)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
by: Claire Roddie, et al.
Published: (2023-08-01)

CACAni : cel shader
by: Cheng, Wei Jie.
Published: (2010)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
by: S. Zweegman, et al.
Published: (2023-05-01)

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
by: Ying Wang, et al.
Published: (2025-02-01)

P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES
by: M Beksac, et al.
Published: (2023-05-01)

El Blau del Cel
by: Marcel Pié Barba, et al.
Published: (2024-08-01)

Jeden cel – dwie drogi
by: Bartosz Włodarski
Published: (2015-08-01)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
by: Monica Dalva, et al.
Published: (2020-01-01)

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
by: Matthew Mei, et al.
Published: (2022-04-01)

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
by: Maximilian Merz, et al.
Published: (2025-01-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Natural killer cels in immunotherapy for cancer
by: E. A. Borobova, et al.
Published: (2019-01-01)

Cel wizyty ad limina Apostolorum
by: Patrycja Kukulska
Published: (2016-12-01)

Despedida do Cel. Newton Cavalcanti
by: Revista de Educação Física
Published: (1933-05-01)

Wiara jako pierwszorzędny cel katechezy
by: Jan Szped
Published: (2014-01-01)

Prospektywny cel badania sprawozdania finansowego
by: Bronisław Micherda
Published: (2010-05-01)